These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 18365957)

  • 1. Secondary progressive multiple sclerosis - clinical course and potential predictive factors.
    Pokryszko-Dragan A; Gruszka E; Bilińska M; Dubik-Jezierzańska M
    Neurol Neurochir Pol; 2008; 42(1):6-11. PubMed ID: 18365957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natural history of secondary-progressive multiple sclerosis.
    Tremlett H; Yinshan Zhao ; Devonshire V
    Mult Scler; 2008 Apr; 14(3):314-24. PubMed ID: 18208898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical assessment of the course of relapsing-remitting multiple sclerosis in patients treated with interferon beta].
    Pokryszko-Dragan A; Bilińska M; Gruszka E; Dubik-Jezierzańska M
    Pol Merkur Lekarski; 2005 Nov; 19(113):654-8. PubMed ID: 16498805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term influence of combined oral contraceptive use on the clinical course of relapsing-remitting multiple sclerosis.
    Gava G; Bartolomei I; Costantino A; Berra M; Venturoli S; Salvi F; Meriggiola MC
    Fertil Steril; 2014 Jul; 102(1):116-22. PubMed ID: 24794311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natural history of multiple sclerosis: a unifying concept.
    Confavreux C; Vukusic S
    Brain; 2006 Mar; 129(Pt 3):606-16. PubMed ID: 16415308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?
    Brown MG; Kirby S; Skedgel C; Fisk JD; Murray TJ; Bhan V; Sketris IS
    Neurology; 2007 Oct; 69(15):1498-507. PubMed ID: 17699802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T2 lesions and rate of progression of disability in multiple sclerosis.
    Mostert JP; Koch MW; Steen C; Heersema DJ; De Groot JC; De Keyser J
    Eur J Neurol; 2010 Dec; 17(12):1471-5. PubMed ID: 20500805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of relapse rate in MS clinical trials.
    Held U; Heigenhauser L; Shang C; Kappos L; Polman C;
    Neurology; 2005 Dec; 65(11):1769-73. PubMed ID: 16344520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Influence of acute aggravations on the development of long-term handicap in relapsing remitting multiple sclerosis: a clinical study in 99 patients].
    Gaillard N; Fabro-Perray P; Faillie JL; Le Bayon A; Castelnovo G; Dupeyron A; Froger J; Pelissier J; Labauge P
    Rev Neurol (Paris); 2007 Jan; 163(1):72-81. PubMed ID: 17304175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical features and disability progression in multiple sclerosis in Tunisia: do we really have a more aggressive disease course?
    Sidhom Y; Damak M; Riahi A; Hizem Y; Mrissa R; Mhiri C; Gouider R
    J Neurol Sci; 2014 Aug; 343(1-2):110-4. PubMed ID: 24980939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the Kurtkze expanded disability status scale and the functional independence measure: measures of multiple sclerosis-related disability.
    Rabadi MH; Vincent AS
    Disabil Rehabil; 2013; 35(22):1877-84. PubMed ID: 23600712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sunlight exposure and sun sensitivity associated with disability progression in multiple sclerosis.
    D'hooghe MB; Haentjens P; Nagels G; Garmyn M; De Keyser J
    Mult Scler; 2012 Apr; 18(4):451-9. PubMed ID: 21952096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Responsiveness and predictive value of EDSS and MSFC in primary progressive MS.
    Kragt JJ; Thompson AJ; Montalban X; Tintoré M; Río J; Polman CH; Uitdehaag BM
    Neurology; 2008 Mar; 70(13 Pt 2):1084-91. PubMed ID: 18184917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive value of clinical characteristics for 'benign' multiple sclerosis.
    Ramsaransing GS; De Keyser J
    Eur J Neurol; 2007 Aug; 14(8):885-9. PubMed ID: 17662009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The natural history of primary progressive MS in British Columbia, Canada.
    Tremlett H; Paty D; Devonshire V
    Neurology; 2005 Dec; 65(12):1919-23. PubMed ID: 16380613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The natural history of primary progressive multiple sclerosis.
    Koch M; Kingwell E; Rieckmann P; Tremlett H
    Neurology; 2009 Dec; 73(23):1996-2002. PubMed ID: 19996074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical predictors of disease progression in multiple sclerosis patients with relapsing onset in a nation-wide cohort.
    Alroughani RA; Akhtar S; Ahmed SF; Al-Hashel JY
    Int J Neurosci; 2015; 125(11):831-7. PubMed ID: 25329929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The natural history of secondary progressive multiple sclerosis.
    Koch M; Kingwell E; Rieckmann P; Tremlett H;
    J Neurol Neurosurg Psychiatry; 2010 Sep; 81(9):1039-43. PubMed ID: 20639385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vitamin D is associated with degree of disability in patients with fully ambulatory relapsing-remitting multiple sclerosis.
    Thouvenot E; Orsini M; Daures JP; Camu W
    Eur J Neurol; 2015 Mar; 22(3):564-9. PubMed ID: 25530281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease.
    Kremenchutzky M; Rice GP; Baskerville J; Wingerchuk DM; Ebers GC
    Brain; 2006 Mar; 129(Pt 3):584-94. PubMed ID: 16401620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.